# Atypical Antipsychotics in Pediatric Populations: Indications Beyond Psychosis

## Introduction

Atypical, or second-generation, antipsychotics are among the most rapidly increasing medication classes prescribed to children and adolescents. While originally developed for psychotic disorders, their use has expanded significantly to include irritability associated with autism, bipolar disorder, tic disorders, and behavioral dysregulation. This expanded prescribing requires vigilant attention to metabolic side effects, thorough informed consent, and adherence to evidence-based indications.

## Mechanism of Action

Second-generation antipsychotics exert their effects through combined dopamine D2 receptor antagonism and serotonin 5-HT2A receptor antagonism. The 5-HT2A blockade modulates dopaminergic activity in a way that reduces extrapyramidal symptoms compared to first-generation agents. Individual medications within this class have variable affinity for histaminic, muscarinic, and alpha-adrenergic receptors, which accounts for their differing side effect profiles. Aripiprazole and brexpiprazole are unique as partial D2 agonists, functioning as dopamine system stabilizers rather than pure antagonists. Clozapine has additional glutamatergic and GABAergic effects that are relevant to its efficacy in treatment-refractory psychosis.

## FDA-Approved Pediatric Indications

Several atypical antipsychotics have FDA approval for specific pediatric indications. Risperidone is approved for irritability in autism spectrum disorder in children aged five and older, for bipolar mania in children aged ten and older, and for schizophrenia in adolescents aged thirteen and older. Aripiprazole is approved for irritability in ASD from age six, bipolar mania from age ten, schizophrenia from age thirteen, and Tourette's disorder from age six. Quetiapine is approved for bipolar mania from age ten and schizophrenia from age thirteen. Olanzapine is approved for bipolar mania and schizophrenia from age thirteen. Paliperidone is approved for schizophrenia from age twelve. Lurasidone is approved for bipolar depression from age ten and schizophrenia from age thirteen.

| Medication | Irritability in ASD | Bipolar Mania | Schizophrenia | Bipolar Depression | Tourette's |
|---|---|---|---|---|---|
| Risperidone | 5+ | 10+ | 13+ | — | — |
| Aripiprazole | 6+ | 10+ | 13+ | — | 6+ |
| Quetiapine | — | 10+ | 13+ | — | — |
| Olanzapine | — | 13+ | 13+ | — | — |
| Paliperidone | — | — | 12+ | — | — |
| Lurasidone | — | — | 13+ | 10+ | — |

## Non-Psychotic Indications in Youth

### Irritability and Aggression in Autism Spectrum Disorder

Risperidone and aripiprazole are the only FDA-approved medications specifically for irritability associated with ASD in children. The target symptoms include tantrums, self-injury, and aggression. It is important to understand that these medications do not treat core autism symptoms such as social communication deficits or restricted interests. Behavioral interventions should be implemented before or alongside pharmacotherapy. The effect sizes for irritability reduction are moderate to large.

### Bipolar Disorder

Atypical antipsychotics are first-line for acute manic and mixed episodes in pediatric bipolar disorder, with aripiprazole, risperidone, quetiapine, and olanzapine all holding FDA approval for bipolar mania in youth. Lurasidone is the only atypical antipsychotic approved for pediatric bipolar depression, filling a significant treatment gap. Long-term maintenance data in youth are limited compared to adult populations.

### Tic Disorders and Tourette Syndrome

Aripiprazole is FDA-approved for Tourette's disorder in children aged six to eighteen. Risperidone and haloperidol are also used for tics but carry higher side effect burdens. Antipsychotics are considered for tic disorders when tics cause significant functional impairment and behavioral interventions such as CBIT have proven insufficient. The treatment goal is typically a 25-50% reduction in tic severity rather than complete suppression.

### Off-Label Uses

Off-label uses in youth include treatment of aggression and behavioral dysregulation in disruptive behavior disorders, though this use should be time-limited and carefully monitored. Adjunctive treatment for treatment-resistant depression and anxiety has limited evidence in youth. Low-dose quetiapine for insomnia is not recommended as first-line. Antipsychotics are sometimes used for PTSD-related hyperarousal and nightmares.

## Metabolic Side Effects

Atypical antipsychotics carry significant cardiometabolic risk in pediatric populations, often exceeding the risk observed in adults receiving the same medications.

### Weight Gain

Olanzapine carries the highest weight gain risk, followed by quetiapine and risperidone. Aripiprazole and lurasidone have relatively lower weight gain liability. Weight gain is most pronounced during the first twelve weeks of treatment and in antipsychotic-naive youth who have never before been exposed to these medications. Average weight gain with olanzapine can exceed seven to eight kilograms in the first twelve weeks alone.

### Metabolic Syndrome Components

The components of metabolic syndrome that may develop include dyslipidemia with elevated triglycerides and LDL and decreased HDL, insulin resistance and new-onset type 2 diabetes mellitus, hypertension, and increased waist circumference. Youth may be at greater metabolic risk than adults for equivalent duration of exposure, making proactive monitoring especially important.

### Monitoring Protocol

The ADA/APA consensus guidelines recommend specific monitoring intervals. At baseline, clinicians should obtain weight, height, BMI, waist circumference, blood pressure, fasting glucose, fasting lipid panel, and HbA1c. Weight and BMI should be rechecked at four weeks and again at eight weeks along with blood pressure and fasting glucose. At twelve weeks, the full panel of weight, BMI, blood pressure, fasting glucose, and fasting lipids should be repeated. Quarterly weight and BMI monitoring should continue thereafter, with annual reassessment of fasting glucose, lipids, and blood pressure.

## Other Adverse Effects

### Neurological

Extrapyramidal symptoms including dystonia, akathisia, and parkinsonism occur at higher rates with risperidone and aripiprazole. Tardive dyskinesia risk increases with duration of exposure and may be irreversible. Akathisia is frequently underdiagnosed because it can mimic anxiety or agitation. Neuroleptic malignant syndrome is rare but life-threatening.

### Endocrine

Hyperprolactinemia is most common with risperidone and paliperidone. Clinical manifestations include galactorrhea, gynecomastia, amenorrhea, and sexual dysfunction. Long-term hyperprolactinemia may affect bone mineral density. Aripiprazole, as a partial D2 agonist, may actually lower prolactin levels.

### Cardiac

QTc prolongation is a concern particularly with ziprasidone and intravenous haloperidol. Baseline and follow-up ECGs should be obtained for medications with known cardiac effects. Myocarditis and cardiomyopathy are rare risks primarily associated with clozapine.

### Sedation

Sedation is most pronounced with quetiapine, olanzapine, and clozapine. It may impair academic performance and daytime functioning. While tolerance to sedation typically develops, it is not guaranteed.

## Prescribing Principles

Atypical antipsychotics should be used only when evidence-based behavioral and psychosocial interventions have been implemented or are insufficient on their own. Informed consent must include discussion of metabolic, neurological, and endocrine risks. Treatment should start at the lowest effective dose with gradual titration. Target symptoms should be clearly defined and reassessed regularly using standardized measures. Periodic dose reduction or discontinuation trials should be planned when clinically appropriate. The rationale for use should be documented, especially when prescribing off-label.

## Clinical Pearls

Metabolic side effects of atypical antipsychotics are often more severe and develop more rapidly in antipsychotic-naive youth than in adults, making proactive monitoring and lifestyle interventions essential from the time of first prescribing. Risperidone-induced hyperprolactinemia is frequently asymptomatic but can have long-term consequences for bone health and reproductive function that warrant ongoing vigilance. Off-label prescribing of antipsychotics for behavioral control without a clear diagnosis or structured treatment plan is a common and concerning practice; clinicians should always define measurable target symptoms and a timeline for reassessment. When an antipsychotic is no longer clearly indicated, a gradual taper with close monitoring is preferred over indefinite continuation.

## References

1. Correll, C. U., Manu, P., Olshanskiy, V., et al. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. *JAMA*, 302(16), 1765-1773.
2. Findling, R. L., Drury, S. S., Jensen, P. S., & Rapoport, J. L. (2011). Practice parameter for the use of atypical antipsychotic medications in children and adolescents. *Journal of the American Academy of Child & Adolescent Psychiatry*, 50(2), 205-210.
3. Stafford, M. R., Mayo-Wilson, E., Loucas, C. E., et al. (2015). Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents, and young adults. *PLoS ONE*, 10(2), e0117166.
4. De Hert, M., Dobbelaere, M., Sheridan, E. M., et al. (2011). Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents. *Journal of Clinical Psychiatry*, 72(4), 555-565.